Enacts provisions relating to cost-sharing for prescription drugs
SB 299 would revise Missouri law governing prescription drug cost-sharing for health maintenance organizations (HMOs) and other health carriers/health benefit plans. The bill requires HMOs to apply the same coinsurance, copayment, and deductible factors to drug prescriptions filled by network pharmacy providers that meet the contract’s cost-determination terms, while still allowing different cost-sharing for generic versus brand-name drugs. It also limits what enrollees can be charged when the plan’s cost-sharing exceeds the drug’s usual and customary retail price, capping the patient’s payment at that retail price and preventing additional charges to the enrollee or plan sponsor.
The bill also addresses pharmacy access and dispensing practices. It preserves existing rules allowing a pharmacist to take assignment of reimbursement rights when an HMO-contracted pharmacy is closed or unavailable in an emergency, and it bars HMOs from contracting with pharmacies or drug distributors that are not licensed or permitted in Missouri. In addition, it prohibits HMOs from imposing non-uniform quantity limits on prescriptions, and it restricts HMOs from forcing changes to a patient’s maintenance drug without the agreement of both the prescriber and the enrollee, except for generic substitution rules already allowed by law.
For health carriers and health benefit plans that cover prescription drugs, SB 299 adds a rule for prescriptions written in a dosage amount not manufactured as a single unit: the plan may impose only one copayment for the combination of manufactured dosages needed to equal the prescribed dose, unless the prescription exceeds a one-month supply. If the plan’s technology cannot process that claim in the normal way, it must provide reimbursement forms for the patient. Like the HMO provisions, the bill also caps patient cost-sharing at the usual and customary retail price when the plan’s required cost-sharing would otherwise be higher.
The overall impact would be to strengthen consumer protections in prescription drug coverage and limit situations where patients pay more than retail price or face multiple charges for a single prescription. It would also constrain plan practices that affect pharmacy network participation, prescription quantity limits, and involuntary medication changes, while leaving room for differential treatment of generic and brand-name drugs and existing generic substitution laws.
There is no recorded committee transcript or vote history in the provided materials, so no formal legislative debate or recorded sentiment is available. Based on the bill text alone, the measure appears consumer- and patient-protective, with likely support from advocates for lower drug costs and pharmacy access. Potential points of contention would be the limits on insurer and HMO pricing flexibility, restrictions on plan design and drug-switching practices, and the administrative burden of implementing the single-copayment and reimbursement requirements.
SB 299 would amend sections 354.535 and 376.386, RSMo, to regulate prescription drug cost-sharing by HMOs, health carriers, and health benefit plans. It would require uniform application of cost-sharing within networks, cap patient payments at the usual and customary retail price when plan cost-sharing is higher, limit non-uniform prescription quantity restrictions, and restrict involuntary changes to maintenance medications. It also adds a one-copayment rule for prescriptions requiring multiple manufactured dosage strengths and requires reimbursement forms if claim technology cannot process that arrangement.
No committee discussion or vote record was provided, so there is no documented legislative sentiment to summarize. From the bill language, the measure is framed as a consumer protection and affordability bill, suggesting likely support from patient advocates and opposition or concern from insurers and managed care organizations due to added coverage mandates and limits on plan cost-sharing practices.
The main likely points of contention are between consumer advocates and insurers/health plans. Supporters would favor lower out-of-pocket costs, protection from multiple copays, and limits on forced medication changes, while opponents may argue the bill restricts plan design, increases administrative complexity, and could raise costs for HMOs and carriers. The provisions on uniform cost-sharing, retail-price caps, and mandatory reimbursement procedures are the most likely areas of dispute.